



# Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





## AML Follow-Up Flow Panel

### Alternative Name

Acute Myeloid Leukemia Follow-Up Flow Panel

### Methodology

Flow Cytometry

### Test Description

Available as global and tech-only. Please provide clinical history including the time after treatment. Prior immunophenotyping at NeoGenomics with Standard or Extended Flow Panel is strongly recommended. Clients who decline full phenotyping and order a global or push-to-global Follow-Up Panel are requested to provide details of the diagnosis by submitting at least one of the following: previous flow cytometry report, previous pathology report, and/or clinical history notes. Markers are cCD3, CD11b, CD13, CD14, CD16, CD19, cCD22, CD33, CD34, CD45, CD64, cCD79a, CD117, CD123, HLA-DR, cMPO, and nTdT (17 markers).

### Clinical Significance

For acute myeloid leukemia (AML) monitoring after diagnosis is established. The standard number of flow events is collected, so this panel is best for diagnosis of relapse or >5% residual disease. This is not a minimal residual disease panel since the standard number of events is collected.

### Specimen Requirements

- **Bone Marrow Aspirate:** 1-2 mL EDTA. Sodium heparin is acceptable. Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.
- **Peripheral Blood:** 1-2 mL EDTA. Sodium heparin is acceptable. Lithium heparin or ACD (pale yellow/no gel separator) is not acceptable. Please provide recent CBC report.
- **Fresh Bone Marrow Core Biopsy:** 1-2cm core (length) tissue in RPMI
- **Fresh/Unfixed Tissue:** 0.2 cm<sup>3</sup> minimum in RPMI
- **Fluids and FNAs:** Equal parts RPMI and specimen volume
- **CSF:** 1-2 mL recommended
- **NY Clients:** Please provide Date and Time of Collection.
- **Note:** Please exclude biopsy needles, blades, and other foreign objects from transport tubes. These can compromise specimen viability and yield, and create hazards for employees.

### Storage & Transportation

Specimens should be received at NeoGenomics within 72 hours from collection to assure sample integrity and acceptable cell viability. **Note:** New York State samples must be received within 48 hours from collection per NYS requirements. Ship same day as drawn whenever possible. Refrigerate specimen. Do not freeze. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

### CPT Code(s)\*

88184x1, 88185x16. Add 88189x1 for global.

### New York Approved

Yes

**Level of Service**

Technical, Global

**Turnaround Time**

24 hours

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

\*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way  
Fort Myers, FL 33912  
Phone: 239.768.0600/ Fax: 239.690.4237  
neogenomics.com  
© 2024 NeoGenomics Laboratories, Inc. All Rights Reserved.  
All other trademarks are the property of their respective owners  
Rev. 050324